Gynecomastia in prepubertal and pubertal men

Current Opinion in Pediatrics

Volumn 20, Issue 4, 2008, Pages 465-470

  Ma, Nina S ^a   Geffner, Mitchell E ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b Saban Research Institute   (United States)

Author keywords

Aromatase; Breast tissue; Gynecomastia; Prepubertal; Pubertal

Indexed keywords

AMIODARONE; ANABOLIC AGENT; ANASTROZOLE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLOMIFENE; CYPROTERONE; DANAZOL; DIAZEPAM; DIGITOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FENOFIBRATE; FINASTERIDE; FLUTAMIDE; HALOPERIDOL; KETOCONAZOLE; METOCLOPRAMIDE; NILUTAMIDE; OMEPRAZOLE; OPIATE; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; RANITIDINE; RESERPINE; RISPERIDONE; SPIRONOLACTONE; TESTOLACTONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ANDROGEN;

ANDROGEN DEFICIENCY; ANDROGEN INSENSITIVITY SYNDROME; CLINICAL TRIAL; GYNECOMASTIA; HISTOPATHOLOGY; HUMAN; PHYSICAL EXAMINATION; PREPUBERTY; PRIORITY JOURNAL; PUBERTY; REVIEW; ADOLESCENT; HYPOGONADISM; MALE; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; ANDROGEN-INSENSITIVITY SYNDROME; ANDROGENS; ESTROGENS; GYNECOMASTIA; HUMANS; HYPOGONADISM; MALE; PUBERTY;

EID: 52449092461     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328305e415     Document Type: Review

References (50)

1. Williams MJ. Gynecomastia: its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963; 34:103-112.
2. Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med 1984; 77:633-638.
3. Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynae-comastiain 954 young males and its relationship to somatometric parameters. Ann Hum Biol 1994; 21:579-587.
4. Abaci A, Buyukgebiz A. Gynecomastia: review. Pediatr Endocrinol Rev 2007; 5:489-499.
5. Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin N Am 2007; 36:497-519.
6. Braunstein GD. Gynecomastia. N Engl J Med 2007; 357:1229-1237.
7. Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490-495.
8. Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990; 116:450-455.
9. Kumanov P, Deepinder F, Robeva R, et al. Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 2007; 41:126-131.
10. Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynaecomastia. Clin Endocrinol (Oxf) 1979; 11:505-521.
11. Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984; 58:492-499.
12. Lazala C, Saenger P. Pubertal gynecomastia. J Pediatr Endocrinol Metab 2002; 15:553-560.
13. Dundar B, Dundar N, Erci T, et al. Leptin levels in boys with pubertal gynecomastia. J Pediatr Endocrinol Metab 2005; 18:929-934.
14. Einav-Bachar R, Phillip M, Aurbach-Klipper Y, Lazar L Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol 2004; 61:55-60.
15. Li RZ, Xia Z, Lin HH, et al. Childhood gynecomastia: a clinical analysis of 240 cases. Chin J Contemp Pediatr 2007; 9:404-406.
16. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356:479-485.
17. Sahin M, Yilmaz H, Gursoy A, et al. Gynaecomastia in a man and hyperoes-trogenism in a woman due to ingestion of nettle (Urtica dioica). N Z Med J 2007; 120:U2803.
18. Gardette V, Vezzosi D, Maiza JC, et al. Gynecomastia associated with fenofibrate. Ann Pharmacother 2007; 41:508-511.
19. Stratakis CA, Batista D, Sabnis G, Brodie A. Prepubertal gynaecomastia caused by medication or the aromatase excess syndrome [letters to the editors]. Clin Endocrinol 2004; 61:779-780.
20. Abe K, Mitsuka T, Kanamori S, et al. Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis. Mod Rheumatol 2007; 17: 511 -513.
21. Diamantopoulos S, Bao Y. Gynecomastia and premature thelarche: a guide for practitioners. Pediatr Rev 2007; 28:e57-e68.
22. Kara C, Kutlu AO, Tosun MS, et al. Sertoli cell tumor causing prepubertal gynecomastia in a boy with Peutz-Jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. Horm Res 2005; 63: 252-256.
23. Lefevre H, BouvattierC, Lahlou N, et al. Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in afamilial case and management with an aromatase inhibitor. Eur J Endocrinol 2006; 154:221-227.
24. Wasniewska M, Raiola G, Galati MC, et al. Nonclassical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia. Eur J Pediatr 2007. [Epub ahead of print]
25. Auchterlonie IA, Cameron J, Wallace AM, et al. Prepubertal gynaecomastia as the presenting feature of late-onset 21-hydroxylase deficiency. Horm Res 1985; 22:94-99.
26. Blackett PR, Freeman DA. Androstenedione aromatization as a cause of gynecomastia in 11-b-hydroxylase and 21-hydroxylase deficiencies. Endocr Pract 1996; 2:90-93.
27. Alonso G, Pasqualini T, Busaniche J, et al. True hermaphroditism in a phenotypic male without ambiguous genitalia: an unusual presentation at puberty. Horm Res 2007; 68:261 -264.
28. Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998; 83:1348-1357.
29. Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348:1855-1865.
30. Martin R, Lin C, Nishi M, et al. Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings. J Clin Endocrinol Metab 2003; 88:3027-3034.
31. Binder G, Iliev I, Dufke A, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005; 90: 484-492.
32. Tiulpakov A, Kalintchenko N, SemitchevaT, et al. A potential rearrangement between CYP1 9 and TRPM7 genes on chromosome 15q21.2 as a cause of aromatase excess syndrome. J Clin Endocrinol Metab 2005; 90:4184-4190.
33. Demura M, Martin R, Shozu M, et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum Mol Genet 2007; 16:2529-2541.
34. Sher E, Migeon C, Berkovitz G. Evaluation of boys with marked breast development at puberty. Clin Pediatr 1998; 37:367-372.
35. Ersoz HO, Onde ME, Terekeci H, et al. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia. Int J Androl 2002; 25:312-316.
36. Swerdlow AJ, Schoemaker MJ, Higgins CD, et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005; 97:1204-1210.
37. Ormandy CJ, Hall RE, Manning DL, et al. Coexpression and cross-regulation of the prolactin and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 1997; 82:3692-3699.
38. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor a and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 2004; 88:69-77.
39. Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002; 87:3893-3901.
40. Melo KF, Mendonca BB, Cillerbeck AC, et al. Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. J Clin Endocrinol Metab 2003; 88:3241 -3250.
41. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; 367:595-604.
42. Buckle R. Danazol therapy in gynaecomastia: recent experience and indications for therapy. Postgrad Med J 1979; 55 (Suppl 5):71 -78.
43. Beck W, Stubbe P. Endocrinological studies of the hypothalamo-pituitary gonadal axis during danazol treatment in pubertal boys with marked gynecomastia. Horm Metab Res 1982; 14:653-657.
44. Zachmann M, Eiholzer U, Muritano M, et al. Treatment of pubertal gynaecomastia with testolactone. Acta Endocrinol Suppl (Copenh) 1986; 279:218-226.
45. Plourde PV, Kulin HE, Santner SJ. Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies. Am J Dis Child 1983; 137: 1080-1082.
46. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004; 145:71 -76.
47. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4428-4433.
48. Wadie GM, Banever GT, Moriarty KP, et al. Ductal carcinoma in situ in a 16-year-old adolescent boy with gynecomastia: a case report. J Pediatr Surg 2005; 40:1349-1353.
49. Liao EC, Kish JB, Hertl MC. Incidental discovery of bilateral breast cancer in a 24-year-old man presenting with gynecomastia. Ann Plast Surg 2007; 58:673-676.
50. Handschin AE, Bietry D, Husler R, et al. Surgical management of gynecomastia: a 10-year analysis. World J Surg 2008; 32:38-44.